News Review: Cott Corporation (USA)(NYSE:COT), ARRIS International plc (NASDAQ:ARRS), Nektar Therapeutics (NASDAQ:NKTR)

On Friday, Shares of Cott Corporation (USA)(NYSE:COT), subtract -9.00% and closed at $12.54 in the last trading session. The last trading range of the stock ranges between $12.46 and $13.66. Cott Corporation ( NYSE : COT ) ( TSX : BCB ) recently declared its results for the third quarter ended October 1, 2016.

THIRD QUARTER 2016 HIGHLIGHTS

Cott accomplished the acquisitions of Eden Springs (“Eden”) and S&D Coffee and Tea (“S&D”) during the quarter, adding businesses with pro forma estimated 2016 revenues of about $950 million.

Cott revenue during the quarter was higher by 17% (20% on a foreign exchange neutral basis) at $885 million contrast to $756 million.

Gross profit raised to $306 million contrast to $233 million and gross margin as a percentage of revenue raised to 34.5% contrast to 30.8%.

Net cash offered by operating activities of $92 million less $39 million of capital expenditures resulted in free cash flow of $53 million, or $67 million on an adjusted basis when apart from $14 million of acquisition, integration and transaction related costs.

ARRIS International plc (NASDAQ:ARRS), jumped 2.98% and closed at $29.02 in the last trading session. The last trading range of the stock ranges between $27.95 and $29.08. The company’s Market capitalization is $5.67 Billion with the total Outstanding Shares of 189.86 million. South African pay television provider MultiChoice recently launched the new DStv Explora 2 decoder from ARRIS International plc (ARRS) to customers in South Africa and Sub-Saharan Africa.

The flagship decoder is the fourth generation of HD PVR devices that ARRIS and MultiChoice have launched together and makes it easier for customers to access MultiChoice’s growing on demand services. In the future, its HEVC technology will reduce the bandwidth needed to stream or download shows, assisting to lower the data charges that customers incur when streaming or downloading content from one of the DStv services.

The device features a streamlined hard drive and ships with a new remote control that features motion-sensor back-lit buttons and a dedicated ShowMax button.

Nektar Therapeutics (NASDAQ:NKTR), jumped 5.34% and closed at $14.41 in the last trading session. The last trading range of the stock ranges between $13.20 and $14.55.The company stock’s 52-week range is $10.52 – $19.98. Nektar Therapeutics (NKTR) recently declared that new Phase 1 clinical data for Nektar’s lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting.  NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and Natural Killer (NK) cell abundance directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.  The results were presented by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in an oral presentation during recently’s session entitled “New Cancer Immunotherapy Agents in Development.”

Leave a Reply

Your email address will not be published. Required fields are marked *